Parion Sciences, a firm committed to developing new treatments to address pulmonary and ocular diseases, recently announced that it was named the Best Late Stage Product Development Company by the Triangle Business Journal and accounting firm BDO. Parion received the award at an event held recently in Cary North Carolina and is now part of the third-annual class of Life Science Award winners. The Life Sciences awards serve to recognize not only individuals but also research organizations that are advancing knowledge in the field. This includes several areas such as biotechnology, biology, genomics, pharmacology and neuroscience.
Parion Sciences is a biopharmaceutical development stage firm focused on development, research and commercialization of products and treatments that might not only improve but also extend the lives of those suffering pulmonary and ocular deficiencies. Parion has a large and diverse pipeline of clinical and pre-clinical candidates to address such diseases via distinct approaches and mechanisms of action. The company has been receiving support and funding from the National Institutes of Health and Cystic Fibrosis Foundation Therapeutics, Inc.
“This year’s list of winners reflect the power, influence and intellect present in our communities within this sector. In the Triangle, the life sciences industry continue to attract companies and individuals whose work and research are being monitored and revered across the globe. This sector continues to lead the Triangle’s economic resurgence,” noted Bryan Michael Hamilton, who is the Triangle Business Journal publisher.
Parion Sciences’ Chief Executive Officer and President Paul Boucher accepted the award, saying: “I am pleased to accept this award on behalf of our dedicated employees and founders. We truly appreciate the recognition and support as we continue to progress our innovative programs through the clinic and potentially to patients in need of new therapies.”
Parion also recently announced the start of the enrollment process for a Phase 2 clinical trial of its product P-1037, a therapy for cystic fibrosis (CF). The trial is called “CLEAN-CF,” referring to “Clearing Lungs with ENaC inhibition in Cystic Fibrosis.” The company’s goal is to enroll 120 patients at 30 different sites, especially within the clinical trials national network of Cystic Fibrosis Foundation Therapeutics Inc. CF patients can be enrolled in this Phase 2 trial irrespective of their genetic mutation.